<- Go Home
Pharnext S.C.A.
Pharnext S.C.A., a clinical-stage biopharmaceutical company, engages in developing novel therapies for neurodegenerative diseases. Its products in clinical development include PXT3003, a synergistic combination of baclofen, naltrexone, and sorbitol formulated as an oral solution for the treatment of charcot-marie-tooth disease type 1A; and PXT864, a novel fixed-dose synergistic combination of baclofen and acamprosate formulated as a pill for neurodegenerative diseases. The company was incorporated in 2007 and is headquartered in Suresnes, France.
Market Cap
EUR 34.00
Volume
1.9K
Cash and Equivalents
EUR 13.2K
EBITDA
-EUR 23.3M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-EUR 19.2M
Profit Margin
11153.39%
52 Week High
EUR 2.00
52 Week Low
EUR 0.00
Dividend
N/A
Price / Book Value
N/A
Price / Earnings
N/A
Price / Tangible Book Value
N/A
Enterprise Value
EUR 26.2M
Enterprise Value / EBITDA
-1.12
Operating Income
-EUR 23.9M
Return on Equity
97.86%
Return on Assets
-277.44
Cash and Short Term Investments
EUR 13.2K
Debt
EUR 26.2M
Equity
-EUR 32.1M
Revenue
EUR 171.9K
Unlevered FCF
N/A
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium